|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RNF207 |
Gene summary for RNF207 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RNF207 | Gene ID | 388591 |
| Gene name | ring finger protein 207 | |
| Gene Alias | C1orf188 | |
| Cytomap | 1p36.31 | |
| Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | Q6ZRF8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 388591 | RNF207 | C21 | Human | Oral cavity | OSCC | 4.04e-11 | 5.14e-01 | 0.2678 |
| 388591 | RNF207 | C38 | Human | Oral cavity | OSCC | 5.20e-04 | 5.83e-01 | 0.172 |
| 388591 | RNF207 | C43 | Human | Oral cavity | OSCC | 1.74e-08 | 1.69e-01 | 0.1704 |
| 388591 | RNF207 | C46 | Human | Oral cavity | OSCC | 1.52e-23 | 6.29e-01 | 0.1673 |
| 388591 | RNF207 | C57 | Human | Oral cavity | OSCC | 3.71e-08 | 3.65e-01 | 0.1679 |
| 388591 | RNF207 | C08 | Human | Oral cavity | OSCC | 1.91e-10 | 1.57e-01 | 0.1919 |
| 388591 | RNF207 | LN46 | Human | Oral cavity | OSCC | 3.45e-10 | 4.61e-01 | 0.1666 |
| 388591 | RNF207 | SYSMH2 | Human | Oral cavity | OSCC | 6.92e-04 | 1.55e-01 | 0.2326 |
| 388591 | RNF207 | SYSMH3 | Human | Oral cavity | OSCC | 4.25e-04 | 1.35e-01 | 0.2442 |
| 388591 | RNF207 | SYSMH4 | Human | Oral cavity | OSCC | 1.18e-03 | 5.79e-02 | 0.1226 |
| 388591 | RNF207 | SYSMH5 | Human | Oral cavity | OSCC | 2.74e-03 | 3.43e-02 | 0.0647 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00605629 | Oral cavity | OSCC | epithelial tube morphogenesis | 149/7305 | 325/18723 | 6.73e-03 | 2.50e-02 | 149 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RNF207 | SNV | Missense_Mutation | rs369840055 | c.26N>A | p.Leu9Gln | p.L9Q | Q6ZRF8 | protein_coding | deleterious(0) | possibly_damaging(0.525) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| RNF207 | SNV | Missense_Mutation | c.1744N>A | p.Gly582Arg | p.G582R | Q6ZRF8 | protein_coding | tolerated_low_confidence(0.53) | benign(0) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RNF207 | SNV | Missense_Mutation | c.1636G>C | p.Glu546Gln | p.E546Q | Q6ZRF8 | protein_coding | deleterious(0.04) | probably_damaging(0.957) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RNF207 | SNV | Missense_Mutation | rs765167255 | c.239N>A | p.Arg80Gln | p.R80Q | Q6ZRF8 | protein_coding | tolerated(0.23) | probably_damaging(0.92) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| RNF207 | SNV | Missense_Mutation | novel | c.1456G>C | p.Glu486Gln | p.E486Q | Q6ZRF8 | protein_coding | tolerated(0.06) | possibly_damaging(0.569) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| RNF207 | SNV | Missense_Mutation | novel | c.137C>T | p.Ala46Val | p.A46V | Q6ZRF8 | protein_coding | deleterious(0) | possibly_damaging(0.575) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RNF207 | SNV | Missense_Mutation | novel | c.770N>T | p.Arg257Met | p.R257M | Q6ZRF8 | protein_coding | deleterious(0.04) | probably_damaging(0.91) | TCGA-VS-A8Q9-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| RNF207 | SNV | Missense_Mutation | rs368780534 | c.1604C>T | p.Thr535Met | p.T535M | Q6ZRF8 | protein_coding | deleterious(0.04) | possibly_damaging(0.87) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| RNF207 | SNV | Missense_Mutation | novel | c.995N>A | p.Pro332His | p.P332H | Q6ZRF8 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| RNF207 | SNV | Missense_Mutation | rs772868363 | c.220G>A | p.Gly74Arg | p.G74R | Q6ZRF8 | protein_coding | deleterious(0.04) | possibly_damaging(0.862) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |